Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15789345 | 0.93 | SIGMAR1 (0.45) | ALDH1A1TSHRSIGMAR1LMNAHTR2A | |
| SCHEMBL2519760 | 0.85 | MAPT (0.35) | ALDH1A1TSHRSIGMAR1LMNAHTR2A | |
| SCHEMBL587972 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL194197 | 0.76 | ALDH1A1 (0.48) | ALDH1A1TSHRSIGMAR1LMNAHTR2A | |
| SCHEMBL2462839 | 0.76 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL3807307 | 0.73 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL7795606 | 0.73 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL23797570 | 0.73 | CHRM2 (0.44) | ALDH1A1TSHRSIGMAR1LMNAHTR2A | |
| SCHEMBL25949 | 0.72 | — | — | |
| SCHEMBL4792651 | 0.70 | ALDH1A1 (0.58) | ALDH1A1CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077038-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069684-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2025265101-A4 | LIPID NANOPARTICLES FOR DELIVERY OF VACCINE FOR PREVENTION OF TUBERCULOSIS | AKAGERA MEDICINES, INC. (US) | 2026-02-05 | — | — | WO | disclosed |
| US-20260007741-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINES | AKAGERA MEDICINES, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2025265101-A1 | LIPID NANOPARTICLES FOR DELIVERY OF VACCINE FOR PREVENTION OF TUBERCULOSIS | AKAGERA MEDICINES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025264937-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINES | AKAGERA MEDICINES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250387462-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS | AKAGERA MEDICINES, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4637810-A2 | LIPID NANOPARTICLES FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS | Akagera Medicines, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-120813370-A | Lipid nanoparticles for preventing tuberculosis or other mycobacterial infections | 阿卡格拉医药公司 | 2025-10-17 | — | — | CN | disclosed |
| WO-2025117732-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2025-06-05 | — | — | WO | disclosed |
| US-20240325525-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024138134-A3 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF CORONAVIRUS INFECTION | AKAGERA MEDICINES, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-12064479-B2 | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof | AKAGERA MEDICINES, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| WO-2024138121-A3 | LIPID NANOPARTICLES FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS | AKAGERA MEDICINES, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024138134-A2 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF CORONAVIRUS INFECTION | AKAGERA MEDICINES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138121-A2 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS | AKAGERA MEDICINES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023230587-A3 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2023230587-A2 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230212578-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069684-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | PHOSPHO1, PLTP, SGMS1 | ALDH1A1 4716/4885TSHR 4047/4885SIGMAR1 371/4885 |
| US-20250387462-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS | CD4, MICA, LNPK | ALDH1A1 4826/4885TSHR 2942/4885SIGMAR1 3159/4885 |
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | PHOSPHO1, PTDSS1, PTDSS2 | ALDH1A1 4475/4885TSHR 4168/4885SIGMAR1 1344/4885 |
| US-20260007741-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINES | TLR9, TLR3, TLR8 | ALDH1A1 4581/4885TSHR 3557/4885SIGMAR1 1252/4885 |
| US-20260077038-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | PHOSPHO1, LNPK, SGMS2 | ALDH1A1 4782/4885TSHR 3848/4885SIGMAR1 740/4885 |
| US-12064479-B2 | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof | PHOSPHO1, PTDSS1, PTDSS2 | ALDH1A1 4475/4885TSHR 4168/4885SIGMAR1 1344/4885 |
| US-20230212578-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA | APOB, APOL1, LPL | ALDH1A1 4258/4885TSHR 2754/4885SIGMAR1 4773/4885 |
| US-20240325525-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | PHOSPHO1, PTDSS1, PTDSS2 | ALDH1A1 4475/4885TSHR 4168/4885SIGMAR1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.